2.41
InspireMD Inc. stock is traded at $2.41, with a volume of 18,371.
It is down -1.63% in the last 24 hours and up +2.12% over the past month.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.
See More
Previous Close:
$2.45
Open:
$2.45
24h Volume:
18,371
Relative Volume:
0.37
Market Cap:
$74.75M
Revenue:
$6.21M
Net Income/Loss:
$-19.92M
P/E Ratio:
-2.2952
EPS:
-1.05
Net Cash Flow:
$-16.76M
1W Performance:
-1.23%
1M Performance:
+2.12%
6M Performance:
-16.90%
1Y Performance:
-3.21%
InspireMD Inc. Stock (NSPR) Company Profile
Name
InspireMD Inc.
Sector
Industry
Phone
972 3 6917691
Address
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NSPR
InspireMD Inc.
|
2.41 | 74.75M | 6.21M | -19.92M | -16.76M | -1.05 |
![]()
ABT
Abbott Laboratories
|
132.28 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
SYK
Stryker Corp
|
373.37 | 147.15B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
BSX
Boston Scientific Corp
|
101.73 | 146.97B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
MDT
Medtronic Plc
|
86.17 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
73.27 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-07-16 | Initiated | Rodman & Renshaw | Buy |
Mar-13-15 | Downgrade | Oppenheimer | Outperform → Perform |
Nov-26-13 | Initiated | Oppenheimer | Outperform |
InspireMD Inc. Stock (NSPR) Latest News
InspireMD’s embolic prevention system gains CE Mark approval - Yahoo Finance
InspireMD receives CE mark approval for CGuard Prime stent system By Investing.com - Investing.com South Africa
InspireMD Gains CE Mark for Stroke Device CGuard Prime - marketscreener.com
InspireMD Gains CE Mark Approval for CGuard® Prime - TipRanks
InspireMD announces CE Mark approval for CGuard Prime EPS - TipRanks
InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke - The Manila Times
InspireMD, Inc. Secures CE Mark Approval for CGuard® Prime EPS Carotid Stent System - Nasdaq
InspireMD Announces CE Mark Approval for CGuard® Prime - GlobeNewswire
InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke - GlobeNewswire Inc.
Millennium Management LLC Has $867,000 Position in InspireMD, Inc. (NYSE:NSPR) - Defense World
Medical device company appoints CFO - The Business Journals
InspireMD appoints Michael Lawless CFO - MSN
Northern Trust Corp Acquires 24,452 Shares of InspireMD, Inc. (NYSE:NSPR) - Defense World
InspireMD names Michael Lawless as new CFO By Investing.com - Investing.com South Africa
InspireMD Appoints Michael Lawless as CFO - marketscreener.com
InspireMD (NSPR) Announces New CFO Appointment | NSPR Stock News - GuruFocus
InspireMD names Michael Lawless as new CFO - Investing.com Australia
InspireMD Holds Annual Stockholders Meeting and Elections - TipRanks
InspireMD CFO Craig Shore to depart, Michael Lawless to succeed - TipRanks
InspireMD Appoints New CFO Amidst Strategic Expansion - TipRanks
InspireMD Announces Appointment Of Michael Lawless As Chief Financial Officer - marketscreener.com
InspireMD Taps Healthcare Veteran Michael Lawless as CFO Ahead of Major US Launch - Stock Titan
Inspire Medical Systems (NYSE:INSP) and InspireMD (NYSE:NSPR) Head-To-Head Contrast - Defense World
OrthoPediatrics (NASDAQ:KIDS) versus InspireMD (NYSE:NSPR) Critical Review - Defense World
Piper Sandler Lowers InspireMD (NYSE:NSPR) Price Target to $4.00 - Defense World
InspireMD Inc. Reports Q1 2025 Financial Results - MSN
InspireMD outlines Q3 2025 FDA approval target for CGuard Prime - MSN
InspireMD Inc’s Earnings Call: Growth Amid Challenges - MSN
InspireMD (NSPR) Sees Price Target Reduction by Piper Sandler | - GuruFocus
InspireMD price target lowered to $4 from $4.50 at Piper Sandler - TipRanks
Piper Sandler cuts InspireMD stock price target to $4.00 By Investing.com - Investing.com South Africa
Piper Sandler cuts InspireMD stock price target to $4.00 - Investing.com Australia
InspireMD (NSPR) Price Target Reduced, FDA Approval Timeline Adj - GuruFocus
InspireMD initiated with a Buy at Lake Street - TipRanks
InspireMD, Inc. (NASDAQ:NSPR) Q1 2025 Earnings Call Transcript - Insider Monkey
InspireMD Inc (NSPR) Q1 2025 Earnings Report Preview: What To Lo - GuruFocus
InspireMD Inc (NSPR) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Operational Challenges By GuruFocus - Investing.com Canada
Earnings call transcript: InspireMD Q1 2025 shows mixed results - Investing.com
InspireMD earnings beat by $0.09, revenue fell short of estimates - Investing.com Canada
InspireMD reports Q1 EPS (22c) vs (21c) last year - TipRanks
InspireMD (NSPR) Posts Slight Increase in Q1 Revenue | NSPR Stoc - GuruFocus
InspireMD Inc (NSPR) Q1 2025 Earnings: Revenue of $1.53M Beats E - GuruFocus
InspireMD Stock Dips On Wider-Than-Expected Q1 Loss, But Retail Is Optimistic - NewsBreak: Local News & Alerts
InspireMD Stock Dips On Wider-Than-Expected Q1 Loss, But Retail Is Optimistic By Stocktwits - Investing.com India
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
InspireMD Reports First Quarter 2025 Financial Results - The Manila Times
InspireMD, Inc. Reports Q1 2025 Financial Results and Anticipates FDA Approval for CGuard™ Prime Carotid Stent System - Nasdaq
Renaissance Technologies LLC Invests $27,000 in InspireMD, Inc. (NYSE:NSPR) - Defense World
INSPIREMD Earnings Preview: Recent $NSPR Insider Trading, Hedge Fund Activity, and More - Nasdaq
InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com - Defense World
InspireMD Inc. Stock (NSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):